Sangeetha Bollini

Sangeetha Bollini is a talented professional with an extensive background in the biopharmaceutical industry.

She currently serves as the Director of Preclinical Operations at Tallac Therapeutics, where she leads operational activities related to preclinical research and development.

Prior to her role at Tallac Therapeutics, Sangeetha gained valuable experience as a Bioanalytical and Program Management Consultant, providing expert guidance to various organizations.

Her previous roles include Director of Program Management at ALX Oncology, where she played a key role in overseeing program strategies and execution.

Sangeetha also served as the Program Management and Assay Development Head, Nonclinical Pharmacology Submissions Lead at Pfizer, showcasing her strong leadership and project management skills in a corporate setting.

Furthermore, she has a background in scientific research, having worked as a Protein Engineer and Assay Development Scientist at Rinat Neuroscience, conducting valuable research in the field.

Her early career includes positions such as a Research Associate at Deltagen and a Researcher at the Center for Blood Research at Harvard Medical School, illustrating her academic foundation and research capabilities.

Sangeetha Bollini's diverse experience across various organizations highlights her expertise in program management, preclinical operations, bioanalytical consulting, and scientific research in the biopharmaceutical sector.